Medication info
Avalin Capsule 75 mg (Pregabalin)

Avalin Capsule 75 mg (Pregabalin)

Prescription medicationHard capsuleOral
Ingredient · strength
Pregabalin›75mg / 1 capsule
Manufacturer / importer
Selbion Co., Ltd.
Appearance
A hard capsule with the upper part being reddish-brown and the lower part white containing white powder
Packaging
30 capsules/bottle, 100 capsules/bottle
Approval status
Active

MFDS item code 201906857 · Approved 2019.09.26

Summary

Main use
Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial-onset seizures
Who takes it
Adults · Children
Adult dose
The total daily dose of pregabalin should be divided into 2 doses and administered orally, with or without food. Since this medicine is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. (See '5. Patients with renal impairment'.) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This medicine may be started at 150 mg per day. Based on the individual patient's response and tolerability, the dose may be increased to 300 mg per day after 3 to 7 days. If needed, it may subsequently be increased at 7-day intervals to a maximum of 600 mg per day. 2) Central neuropathic pain Adults: This medicine may be started at 150 mg per day. Based on the individual patient's response and tolerability, the dose may be increased to 300 mg per day after 1 week. After an additional week, it may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See '4. Discontinuation of treatment'.) 2. Epilepsy Adults: This medicine may be started at 150 mg per day. Based on the individual patient's response and tolerability, the dose may be increased to 300 mg per day after 1 week. If needed, it may subsequently be increased at 7-day intervals to a maximum of 600 mg per day. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg ~ 450 mg per day. The initial dose is 75 mg twice daily (150 mg per day), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg per day). For patients who do not experience sufficient benefit at a dose of 300 mg per day, the dose may be increased within 1 week to 225 mg twice daily (450 mg per day). Clinical studies have also been conducted at a dose of 600 mg per day, but there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg per day are not recommended. 4. Discontinuation of treatment Based on current clinical experience, if treatment with this medicine is discontinued, it should be tapered gradually over at least 1 week. 5. Patients with renal impairment This medicine is primarily excreted unchanged by the kidneys after entering the systemic circulation. Its clearance is directly affected by creatinine clearance; therefore, dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the formula below. This medicine is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose determined according to renal function, an immediate supplemental dose should be administered after each 4-hour hemodialysis session. [Table 1]. Pregabalin dose based on renal function Creatinine clearance (CLcr), (mL/min) | Total daily dose of pregabalin a | Method of administration | Starting dose (mg/day) | Maximum dose (mg/day) ≥60 | 150 | 600 | BID or TID ≥30 -<60 | 75 | 300 | BID or TID ≥15 -<30 | 25-50 | 150 | QD or BID <15 | 25 | 75 | QD Supplemental dose after hemodialysis | 25 | 100 | Single dose b TID = Total daily dose divided into 3 doses BID = Total daily dose divided into 2 doses QD = Once daily a: The total daily dose (mg/day) should be divided as specified under the method of administration. b: Supplemental dose refers to an additional dose administered as a single dose. 6. Patients with hepatic impairment Dose adjustment is not necessary in patients with hepatic impairment. 8. Elderly patients (65 years of age or older) Dose reduction may be necessary in elderly patients with impaired renal function.
Child dose
Children under 12 years of age: Administration is not recommended because there are insufficient safety and efficacy data. Adolescent patients aged 12 ~17 years: Administration is not recommended because there are insufficient safety and efficacy data.

Ingredients

Manufacturer
Selbion Co., Ltd.

Efficacy & effects

Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial-onset seizures

  • Peripheral neuropathic pain
  • central neuropathic pain
  • partial seizures
  • fibromyalgia
View approved original text

This medication is used to relieve pain caused by peripheral and central neuropathy in adults. It can also be utilized as an adjunctive treatment for partial seizures in patients with epilepsy to help control symptoms. Additionally, it is effective in relieving pain associated with fibromyalgia. It is used to improve symptoms of various neurological diseases.

How to take

Adult dose

The total daily dose of pregabalin should be divided into 2 doses and administered orally, with or without food. Since this medicine is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. (See '5. Patients with renal impairment'.) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This medicine may be started at 150 mg per day. Based on the individual patient's response and tolerability, the dose may be increased to 300 mg per day after 3 to 7 days. If needed, it may subsequently be increased at 7-day intervals to a maximum of 600 mg per day. 2) Central neuropathic pain Adults: This medicine may be started at 150 mg per day. Based on the individual patient's response and tolerability, the dose may be increased to 300 mg per day after 1 week. After an additional week, it may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See '4. Discontinuation of treatment'.) 2. Epilepsy Adults: This medicine may be started at 150 mg per day. Based on the individual patient's response and tolerability, the dose may be increased to 300 mg per day after 1 week. If needed, it may subsequently be increased at 7-day intervals to a maximum of 600 mg per day. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg ~ 450 mg per day. The initial dose is 75 mg twice daily (150 mg per day), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg per day). For patients who do not experience sufficient benefit at a dose of 300 mg per day, the dose may be increased within 1 week to 225 mg twice daily (450 mg per day). Clinical studies have also been conducted at a dose of 600 mg per day, but there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg per day are not recommended. 4. Discontinuation of treatment Based on current clinical experience, if treatment with this medicine is discontinued, it should be tapered gradually over at least 1 week. 5. Patients with renal impairment This medicine is primarily excreted unchanged by the kidneys after entering the systemic circulation. Its clearance is directly affected by creatinine clearance; therefore, dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the formula below. This medicine is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose determined according to renal function, an immediate supplemental dose should be administered after each 4-hour hemodialysis session. [Table 1]. Pregabalin dose based on renal function Creatinine clearance (CLcr), (mL/min) | Total daily dose of pregabalin a | Method of administration | Starting dose (mg/day) | Maximum dose (mg/day) ≥60 | 150 | 600 | BID or TID ≥30 -<60 | 75 | 300 | BID or TID ≥15 -<30 | 25-50 | 150 | QD or BID <15 | 25 | 75 | QD Supplemental dose after hemodialysis | 25 | 100 | Single dose b TID = Total daily dose divided into 3 doses BID = Total daily dose divided into 2 doses QD = Once daily a: The total daily dose (mg/day) should be divided as specified under the method of administration. b: Supplemental dose refers to an additional dose administered as a single dose. 6. Patients with hepatic impairment Dose adjustment is not necessary in patients with hepatic impairment. 8. Elderly patients (65 years of age or older) Dose reduction may be necessary in elderly patients with impaired renal function.

Child dose

Children under 12 years of age: Administration is not recommended because there are insufficient safety and efficacy data. Adolescent patients aged 12 ~17 years: Administration is not recommended because there are insufficient safety and efficacy data.

Precautions

This medication may increase the risk of suicidal thoughts or behavior, so any changes in mood or behavior during treatment should be reported to a doctor immediately. Patients with hypersensitivity to this medication should not take it. Diabetic patients should be cautious as weight gain may require adjustments to the dosage of blood sugar control medications. If signs of allergic reactions, such as angioedema, occur, discontinue the medication immediately. Elderly patients should exercise particular caution during the initial phase of treatment due to the risk of falls or injuries from dizziness or drowsiness. If blurred vision or changes in eyesight occur, discontinuing this medication may help improve symptoms. When discontinuing this medication, withdrawal symptoms such as insomnia, headaches, and anxiety may occur, so it is essential to consult with healthcare providers. Patients with a history of substance abuse may be at higher risk of misuse and dependence on this medication and should use it cautiously. Patients with reduced renal function may require dosage adjustments. Patients with heart disease or congestive heart failure should use caution while taking this medication. Caution is needed when taking this medication with opioids due to the increased risk of central nervous system suppression. Patients with compromised respiratory function or the elderly may have a higher risk of severe respiratory depression and may require dose adjustments. Pregnant women should avoid this medication during early pregnancy as it may affect the fetus, and women of childbearing age should use effective contraception. Lactating women should discontinue breastfeeding or consult with healthcare professionals as this medication can pass into breast milk. This medication can cause dizziness and drowsiness, thus caution is advised during activities requiring alertness such as driving or operating machinery. Rarely, severe skin reactions may occur, so if symptoms such as skin rash or swelling appear, discontinue use immediately and consult a healthcare professional. In cases of overdose, symptoms such as altered consciousness, drowsiness, and confusion may occur, necessitating immediate medical attention. This medication should be stored safely out of reach of children or others who may easily access it.

Side effects

Suicidal thoughts, suicidal behavior, depression, abnormal changes in mood and behavior, angioedema, facial swelling, periorbital swelling, upper respiratory tract swelling, dizziness, drowsiness, loss of consciousness, confusion, mental disorders, blurred vision, visual changes, insomnia, headache, nausea, anxiety, diarrhea, influenza-like illness, restlessness, suicidal ideation, pain, seizures, hyperhidrosis, misuse, abuse, dependence, congestive heart failure, severe respiratory depression, impaired respiratory function, vomiting, abdominal distension, constipation, dry mouth, bloating, excessive salivation, gastroesophageal reflux disease, oral sensory impairment, ascites, dysphagia, pancreatitis, sweating, papular rash, urticaria, cold sweats, muscle cramps, arthralgia, back pain, limb pain, cervical spasms, joint swelling, myalgia, muscle spasm, neck pain, muscle rigidity, rhabdomyolysis, urination disorders, incontinence, reduced urination, renal failure, erectile dysfunction, delayed ejaculation, sexual dysfunction, dysmenorrhea, amenorrhea, mastalgia, nipple discharge, gynecomastia, peripheral edema, edema, gait abnormalities, falls, feeling drunk, paresthesia, fatigue, tightening sensation in the chest, generalized edema, pain, fever, chills, weakness, thirst, weight gain, elevated alanine aminotransferase, increased serum creatine phosphokinase, elevated aspartate aminotransferase, increased blood glucose, decreased platelet count, decreased potassium levels, increased serum creatinine, decreased white blood cell count, rhinosinusitis, neutropenia, increased appetite, anorexia, hypoglycemia, confusion, disorientation, irritability, sense of well-being, decreased libido, depersonalization, paraphilia, anxiety, mood swings, decreased emotional response, elevated emotional response, difficulty finding appropriate terminology, hallucinations, abnormal dreams, increased libido, panic attacks, impulsivity, flat affect, ataxia, abnormal coordination, balance disorders, amnesia, attention disorders, memory disorders, tremors, speech disturbance, sensory abnormalities, sensory reduction, sedation, somnolence, cognitive impairment, nystagmus, speech disorder, hypertrophic muscle spasms, decreased reflexes, motor abnormalities, psychomotor agitation, position-related dizziness, hyperesthesia, burning sensation, activity tremor, syncope, stupor, psychomotor retardation, olfactory disturbances, taste loss, writing difficulties, diplopia, hyperacusis, first-degree atrioventricular block, tachycardia, sinus bradycardia, sinus tachycardia, sinus arrhythmia, hypotension, hypertension, flushing, facial flushing, peripheral coldness, dyspnea, epistaxis, cough, nasal congestion, rhinitis, snoring, throat tension, nasal dryness, keratitis, pulmonary edema, tongue swelling, itching, Stevens-Johnson syndrome, toxic epidermal necrolysis, urinary retention, gynecomastia, lethargy, delirium, paralysis (facial paralysis), affective disorder, drowsiness, confusion state, agitation, restlessness, worsening of spasms

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to protect it from moisture and air. It is advisable to maintain the storage temperature between 15 to 30 degrees Celsius. This helps to preserve the efficacy and safety of the medication for an extended period.

Appearance and packaging

Appearance

A hard capsule with the upper part being reddish-brown and the lower part white containing white powder

Package unit

30 capsules/bottle, 100 capsules/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.